Redeye publishes a follow-up note subsequent to yesterday's conference call concerning sunday's CRL ...
Redeye comments on yesterday’s press release from Xspray that it has successfully scaled up its ASP ...
The share price has been relatively weak despite net sales and operating profit looking set to impro...
Q1 sales hurt by lower US sales, but other regions contributed well Fine-tuned sales estimates, but ...
Redeye comments on the announcement of a SEK120m rights issue of units.
En nedskrivning tyngde resultatet för fjärde kvartalet och under januari lanserade Soltech uppdatera...
Negativ organisk tillväxt… Den organiska tillväxten var -9% i Q1.
Inför Q1-rapporten räknar Analysguiden med tillväxt på samtliga marknader och en stärkt rörelsemargi...
Redeye ser positivt på helgens nyhet att Eisai och BioArctic ingått ett forskningsutvärderingsavtal ...
Redeye provides its initial comments on yesterday evening’s news that Xbrane has received a CRL from...
Redeye comments on Embracer’s announcement that it intends to split-up its business into three liste...
Vitrolife’s Q1 shows that the headwind for Genetics will likely last until mid-2024.
Redeye updates on Invisio ahead of its Q1-results (due 7 May) where we expect a strong order intake ...
Redeye comments on Scandion Oncology announcing a cSEK60m rights issue.
Redeye updates its estimates and valuation following Vitec releasing its Q1 2024 report.
Elanders presented a mixed Q1 report, with a high single-digit organic sales decline, as Fashion saw...
Q1 weaker than expected... ...but outlook remains bright Low valuation and leverage on market, lower...
Redeye considers the declaration of intents for the TO6 warrants from Xspray's largest shareholders ...
Arctic Blue Beverages AB (”Arctic Blue Beverages” eller ”Bolaget”) meddelade den 18 april 2024 att B...
Flat organic sales growth, due to Genetics EBITDA revised down 1.
